

Brunei International Medical Journal

OFFICIAL PUBLICATION OF
THE MINISTRY OF HEALTH
AND
UNIVERSITI BRUNEI DARUSSALAM

Volume 19

28 September 2023 (12 Rabiulawal 1445H)

TURNER SYNDROME: DIAGNOSIS AND TREATMENT CHALLENGE IN A DEVELOPING COUNTRY.

Siska Mayasari LUBIS, Melda DELIANA, Clara DEVINA.

Child Health Department, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.

ABSTRACT

Turner syndrome is one of the rare genetic diseases when there is a partial or complete missing of the X chromosome in females. Short stature and late puberty are the most common manifestations and the main target of treatment. However, not all Turner syndrome patients can get both treatments. We herein report the challenges in treating Turner syndrome patients in a developing country with a chief complaint of short stature and whose breasts had not grown. The patient was diagnosed late because the parents thought her short stature was normal. The patient denied growth hormone therapy because the treatment was expensive and the government's insurance program did not cover it. Therefore, we optimized her treatment in another aspect, which was inducing her puberty with low-dose estrogen. In developing countries, late diagnosis, expensive treatment, and no insurance coverage are challenges in treating patients with rare diseases such as Turner syndrome.

Keyword: Chromosomes, Diagnosis, Developing countries, Treatment, Turner syndrome.

Brunei Int Med J. 2023;19:49-53

Brunei International Medical Journal (BIMJ) Official Publication of The Ministry of Health and Universiti Brunei Darussalam

EDITORIAL BOARD

Editor-in-Chief	Ketan PANDE
Sub-Editors	Vui Heng CHONG William Chee Fui CHONG
Editorial Board Members	Muhd Syafiq ABDULLAH Alice Moi Ling YONG Ahmad Yazid ABDUL WAHAB Jackson Chee Seng TAN Pemasiri Upali TELISINGHE Pengiran Khairol Asmee PENGIRAN SABTU Dayangku Siti Nur Ashikin PENGIRAN TENGAH

INTERNATIONAL EDITORIAL BOARD MEMBERS

Lawrence HO Khok Yu (Singapore)	Chuen Neng LEE (Singapore)
Wilfred PEH (Singapore)	Emily Felicia Jan Ee SHEN (Singapore)
Surinderpal S BIRRING (United Kingdom)	Leslie GOH (United Kingdom)
John YAP (United Kingdom)	Ian BICKLE (United Kingdom)
Nazar LUQMAN (Australia)	Christopher HAYWARD (Australia)
Jose F LAPENA (Philippines)	

Advisor

Wilfred PEH (Singapore)

Past Editors-in-Chief

Nagamuttu RAVINDRANATHAN
Kenneth Yuh Yen KOK
Chong Vui Heng
William Chong Chee Fui

Proof reader

John WOLSTENHOLME (CfBT Brunei Darussalam)

Aim and Scope of Brunei International Medical Journal

The Brunei International Medical Journal (BIMJ) is a six monthly peer reviewed official publication of the Ministry of Health under the auspices of the Clinical Research Unit, Ministry of Health, Brunei Darussalam.

The BIMJ publishes articles ranging from original research papers, review articles, medical practice papers, special reports, audits, case reports, images of interest, education and technical/innovation papers, editorials, commentaries and letters to the Editor. Topics of interest include all subjects that relate to clinical practice and research in all branches of medicine, basic and clinical including topics related to allied health care fields. The BIMJ welcomes manuscripts from contributors, but usually solicits reviews articles and special reports. Proposals for review papers can be sent to the Managing Editor directly. Please refer to the contact information of the Editorial Office.

Instruction to authors Manuscript submissions

All manuscripts should be sent to the Managing Editor, BIMJ, Ministry of Health, Brunei Darussalam; e-mail: editor-in-chief@bimjonline.com. Subsequent correspondence between the BIMJ and authors will, as far as possible via should be conducted via email quoting the reference number.

Conditions

Submission of an article for consideration for publication implies the transfer of the copyright from the authors to the BIMJ upon acceptance. The final decision of acceptance rests with the Editor-in-Chief. All accepted papers become the permanent property of the BIMJ and may not be published elsewhere without written permission from the BIMJ.

Ethics

Ethical considerations will be taken into account in the assessment of papers that have experimental investigations of human or animal subjects. Authors should state clearly in the Materials and Methods section of the manuscript that institutional review board has approved the project. Those investigators without such review boards should ensure that the principles outlined in the Declaration of Helsinki have been followed.

Manuscript categories

Original articles

These include controlled trials, interventional studies, studies of screening and diagnostic tests, outcome studies, cost-effectiveness analyses, and large-scale epidemiological studies. Manuscript should include the following; introduction, materials and methods, results and conclusion. The objective should be stated clearly in the introduction. The text should not exceed 2500 words and references not more than 30.

Review articles

These are, in general, invited papers, but unsolicited reviews, if of good quality, may be considered. Reviews are systematic critical assessments of

literature and data sources pertaining to clinical topics, emphasising factors such as cause, diagnosis, prognosis, therapy, or prevention. Reviews should be made relevant to our local setting and preferably supported by local data. The text should not exceed 3000 words and references not more than 40.

Special Reports

This section usually consist of invited reports that have significant impact on healthcare practice and usually cover disease outbreaks, management guidelines or policy statement paper.

Audits

Audits of relevant topics generally follow the same format as original article and the text should not exceed 1,500 words and references not more than 20.

Case reports

Case reports should highlight interesting rare cases or provide good learning points. The text should not exceed 1000 words; the number of tables, figures, or both should not be more than two, and references should not be more than 15.

Education section

This section includes papers (i.e. how to interpret ECG or chest radiography) with particular aim of broadening knowledge or serve as revision materials. Papers will usually be invited but well written paper on relevant topics may be accepted. The text should not exceed 1500 words and should include not more than 15 figures illustration and references

three relevant references should be included. Only images of high quality (at least 300dpi) will be acceptable.

Technical innovations

This section include papers looking at novel or new techniques that have been developed or introduced to the local setting. The text should not exceed 1000 words and should include not more than 10 figures illustration and references should not be more than 10.

Letters to the Editor

Letters discussing a recent article published in the BIMJ are welcome and should be sent to the Editorial Office by e-mail. The text should not exceed 250 words; have no more than one figure or table, and five references.

Criteria for manuscripts

Manuscripts submitted to the BIMJ should meet the following criteria: the content is original; the writing is clear; the study methods are appropriate; the data are valid; the conclusions are reasonable and supported by the data; the information is important; and the topic has general medical interest. Manuscripts will be accepted only if both their contents and style meet the standards required by the BIMJ.

Authorship information

Designate one corresponding author and provide a complete address, telephone and fax numbers, and e-mail address. The number of authors of each paper should not be more than twelve; a greater number requires justification. Authors may add a publishable footnote explaining order of authorship.

Group authorship

If authorship is attributed to a group (either solely or in addition to one or more individual authors), all members of the group must meet the full criteria and requirements for authorship described in the following paragraphs. One or more authors may take responsibility 'for' a group, in which case the other group members are not authors, but may be listed in an acknowledgement.

Authorship requirement

DISCLAIMER

All articles published, including editorials and letters, represent the opinion of the contributors and do not reflect the official view or policy of the Clinical Research Unit, the Ministry of Health or the institutions with which the contributors are affiliated to unless this is clearly stated. The appearance of advertisement does not necessarily constitute endorsement by the Clinical Research Unit or Ministry of Health, Brunei Darussalam. Furthermore, the publisher cannot accept responsibility for the correctness or accuracy of the advertisers' text and/or claim or any opinion expressed.

sign, and the analysis and interpretation of the data (where applicable); to have made substantial contributions to the writing or revision of the manuscript; and to have reviewed the final version of the submitted manuscript and approved it for publication. Authors will be asked to certify that their contribution represents valid work and that neither the manuscript nor one with substantially similar content under their authorship has been published or is being considered for publication elsewhere, except as described in an attachment. If requested, authors shall provide the data on which the manuscript is based for examination by the editors or their assignees.

Financial disclosure or conflict of interest

Any affiliation with or involvement in any organisation or entity with a direct financial interest in the subject matter or materials discussed in the manuscript should be disclosed in an attachment. Any financial or material support should be identified in the manuscript.

Copyright transfer

In consideration of the action of the BIMJ in reviewing and editing a submission, the author/s will transfer, assign, or otherwise convey all copyright ownership to the Clinical Research Unit, RIPAS Hospital, Ministry of Health in the event that such work is published by the BIMJ.

Acknowledgements

Only persons who have made substantial contributions but who do not fulfill the authorship criteria should be acknowledged.

Accepted manuscripts

Authors will be informed of acceptances and accepted manuscripts will be sent for copyediting. During copyediting, there may be some changes made to accommodate the style of journal format. Attempts will be made to ensure that the overall meaning of the texts are not altered. Authors will be informed by email of the estimated time of publication. Authors may be requested to provide raw data, especially those presented in graph such as bar charts or figures so that presentations can be constructed following the format and style of the journal. Proofs will be sent to authors to check for any mistakes made

UNICENTRIC CASTLEMAN'S DISEASE PRESENTING AS A BREAST LUMP.

WONG Winn Lung¹, Mohammad Alif YUNUS¹, Mahfida MAHAT².

¹Department of General Surgery, and ²Department of Pathology, Hospital Melaka, Malaysia.

ABSTRACT

Castleman's disease is a rare and complex lymphoproliferative disease with unknown etiology. It can be classified clinically into unicentric or multicentric and histologically into hyaline vascular or plasmacytic variants. Unicentric Castleman's disease in breast is rarely reported worldwide. We report a case of a young lady presenting with complaint of solitary right breast lump, for which she underwent excision biopsy and was diagnosed of having unicentric Castleman's disease of breast, hyaline vascular variant.

Keywords: Breast, Castleman Disease, Lymphoproliferative disorders, Neoplasm, Unicentric.

INTRODUCTION

Castleman's disease (CD), also known as giant angiofollicular lymphoid hyperplasia, is a rare complex lymphoproliferative disease first described by Benjamin Castleman in a cohort study of patients with hyperplastic mediastinal lymph nodes.^{1,2} It is a rare disease of unknown etiology, categorized into two clinical entities; unicentric (localised) and multicentric (systemic). Histologically classified into hyaline vascular or plasma cell variant.^{3,4} Unicentric Castleman disease (UCD) accounts for nearly 90% of CD.⁵ Most of the patients have no specific imaging features and diagnosis of CD is made with histological findings post-surgical resection.¹ Study showed most uni-

centric cases involved lymph nodes in thorax, neck and abdomen.⁵ There was no data worldwide regarding the prevalence of breast CD and consensus on management for breast CD. Breast CD presentation may mimic other benign or malignant breast condition,⁵ thus it is of paramount that prompt diagnosis need to be made for subsequent management. There are only six previously reported cases of breast CD, thus more publication are needed to improve knowledge about the disease. We report a case of a young lady presenting with complaint of solitary right breast lump, for which she underwent excision biopsy and was diagnosed of having unicentric Castleman's disease of breast, hyaline vascular variant.

Corresponding author: Wong Winn Lung, General Surgery Department, Hospital Melaka, Jalan Mufti Haji Khalil, 75400, Melaka, Malaysia.
email: alex.wwl91@gmail.com;
Phone: +60176807878

CASE REPORT

A 30 years old Malay lady, with no comorbidi-

comorbidity, presented with complaint of right breast lump for 1 month period, otherwise no nipple discharge, no overlying skin changes, with no increase in size of the lump. She also denied family history of breast malignancy, or taking any hormonal therapy. Clinical examination reviewed a mobile, firm lump measuring about 3x3cm in size, located in the right inner lower quadrant of breast about 5cm from nipple areolar complex. Otherwise, no palpable lymph nodes were found in the bilateral axillae or neck.

Ultrasound of breast (Figure 1) was done, which showed well defined lobulated hypoechoic lesion seen in 5 o'clock position 5cm from nipple, measuring about 3.2 x 1.9 x 2.5cm. Core needle biopsy of the lump was performed which showed features suggestive of lymphoid stroma corresponding to primary follicle of lymph node. Thus, surgery of excision biopsy was offered to patient.

Surgery was scheduled as daycare elective case. Excision biopsy of right breast lump was performed. Intraoperatively the lump was deep to breast tissue lying just above pectoralis muscle layer. Lump was excised wholly with rough measurement about 4x4cm in size.

Histopathological examination (Fig. 2) showed well-encapsulated lymphoid tissue with follicular hyperplasia. Lymphoid follicle showed broad mantle zone with small lympho-




Figure 1: Ultrasonography images of right breast lump, which displayed well defined hypoechoic lesion.




Figure 2: (a) Lymphoid follicle shows broad mantle zone consists of small lymphocytes arranged in layers giving an onion skin appearance at x200 magnification (H&E x200), (b) at x400 magnification and (c) Penetration of the mantle zone by vessels ensheathed with collagen, giving a lollipop appearance. (H&E x200). (Click to enlarge image)

cytes arranged in layers giving an onion skin appearance. Some of the hyaline follicles showed penetration of the mantle zone by vessels (lollipop appearance) The interfollicular areas showed increased vascular network with hyalinization.

Immunohistochemical studies demonstrated that CD3, CD5, CD20 displayed mixed population of T and B cells and BCL2 showed a reactive pattern. Ki67, CD10 and BCL6 highlighted germinal centres, while Cyclin D1 stained negative. With the given result, conclusion was consistent with Castleman disease, hyaline vascular variant. Patient was followed up in our clinic about 1 year from surgery. She remains clinically well, and clinical examination revealed no other lymphadenopathy.

Patient was well and reviewed 1 month post-surgery, with excision scar site completely healed. Clinical examination did not reveal any other palpable nodes or breast lump.

DISCUSSION

Castleman's disease (CD) is a rare lymphoproliferative disease for which the primary etiology and pathogenesis still remain largely unknown.⁵ Unicentric disease constituted most of the CD cases, usually has a benign course and can be treated by surgical excision alone; while multicentric disease has worse prognosis and necessitates adjuvant treatment.⁵ Studies by Blankenship ME et al, stated that localised disease has low risk of malignancy with 100% 5 year survival rate and cured after surgical excision of lesion.⁷

Clinically, UCD symptoms are closely linked to its pathological type. Most patients are asymptomatic and follow a benign course.¹ UCD in breast is rare and may present as painless breast lump or axillary lymphadenopathy which can mimic breast cancer.⁸ UCD affects both gender equally, with most patients present at 3rd to 5th decades of life. However, there are cases reported in paediatric age group as young as 2 months.² Prior reported cases revealed patient's age ranging 15 - 80 years, with most presented with solitary breast lump except one case reports that

patient presented with both breast and axillary nodule (Table I). In this case, patient is young lady about 30 years of age and presented with non-progressive breast lump for 2 years. Clinically demonstrate well defined lump mimicking benign breast lump.

In UCD, imaging with ultrasonography showed uniform hypoechoic lesion and Doppler ultrasonography showed peripheral hypervascularity. Megumi Fukuoka et al reported a case of breast CD where ultrasonography showed hypoechoic mass with Doppler signal detected vascularities in the mass. Magnetic resonance imaging (MRI) was done and demonstrated hyperintense lesion on T2-weighted imaging, with fast washout enhancement picture at the peripheries.⁸ Computed tomography (CT) scan showed homogenous enhancing mass with early rapid enhancement during arterial phase but decrease in portal venous phase.² In our case report, the patient underwent ultrasound of breast with well-defined lobulated hypoechoic lesion. CT scan of thorax, abdomen was performed after surgery which showed absence of other lymphadenopathy.

There are two main pathological subtypes, namely hyaline vascular variant (HVV) and plasma cell variant (PCV). Generally, unicentric diseases are associated with HVV while systemic diseases are associated with PCV.² Histological and immunohistochemical studies after surgical resection are needed for definite diagnosis of UCD.¹ Histology examination of HVV showed abundant hyalinized vessels, surrounding small lymphocytes in peripheral wide zone and characteristic 'onion-peel' appearance in germinal center due to concentrically arranged mantle zone.^{1,4}

Immunohistochemical studies showed Ki67, BCL-6 and CD10 stained positive in germinal centre, CD20 stained positive in B lymphocyte and CD3 and CD5 stained positive in T lymphocytes. Cyclin D1, BCL-2, CD56 and

TDT stained negative.⁹ Prior case reports showed all patients presented with breast CD are of hyaline vascular variant (table I). In this reported case, histological examination and immunohistochemistry demonstrated similar findings with previously reported cases, thus diagnosis of Castleman disease with hyaline vascular variant was made.

The mainstay of treatment for hyaline vascular type UCD is still complete surgical resection, with good outcome and 100% 5 year survival rate reported.⁷ In study by Talat N et al, mortality after 10 years following lymph node excision in axilla, groin or neck were rare.⁶ However it was significantly more common in lesion found in retroperitoneum, mediastinum, abdomen and pelvis. If surgery is not feasible, debulking surgery can be considered if patients present with local symptoms or risk of compression to surrounding structures. Previous case reports showed most patients underwent breast lump excision only with two patients required additional axillary dissection (Table I). Case reported by Rene Aloisio et al required breast lump excision and axillary dissection as patient presented with both axillary and breast node; while Fama F et al reported their patient required axillary dissection as frozen section of intramammary node showed lymphoid proliferation with germinal center hyalinisation. There was no study on optimal surveillance follow up for breast UCD post surgical resection. Most patients reported before remain disease free at 6 months to 2 years; only one case reported recurrence at supraclavicular adenopathy at 3 months post surgery where this patient was treated with cycles of prednisolone (Table I). Our patient was follow up post surgical resection with clinical assessment, at 1 year post surgery patient does not demonstrate any recurrence.

CONCLUSION

In conclusion, CD itself is a rare disease and may manifest in breast as breast UCD. Breast CD presentation is non specific and may mimic other benign or malignant breast disease thus making diagnosing breast CD a challenge. Prompt diagnosis and early surgical intervention is beneficial as most patients with breast CD showed good clinical outcome and prognosis.

CONFLICT OF INTEREST

The authors have no conflicts of interest

ACKNOWLEDGEMENT

We acknowledge the help of Dr Mahfida Mahat, anatomical pathologist for providing us with pictograph of histology slide of the specimen.

REFERENCES

- 1: Na Ren, Lei Ding, Erna Jia, Jinru Xue. Recurrence in Unicentric Castleman's Disease Postoperatively: A Case Report and Literature Review. *BMC Surgery.* 2018; 18:1. (DOI:10.1186/s12893-017-0334-7)
- 2: Seth J. Kligerman, Aaron Auerbach, Teri J. Franks, Jeffrey R. Galvin. Castleman Disease of the Thorax: Clinical, Radiologic, and Pathologic Correlation. *RadioGraphics.* 2016; 36:1309-1332. (DOI:10.1148/rg.2016160076)
- 3: Rene Aloisio da Costa Vieira, Jorge Shigueo Kunizaki, Abaete Leite do Canto, et al. Localized Castleman's disease in the breast. *Int J Surg Case Rep.* 2013; 4(3): 325-329 (DOI:10.1016/j.ijscr.2012.12.017)
- 4: H. Gassara et al. Unicentric Castleman Disease: An Unusual Localization In The Breast. *J.I. M. Sfax.* 2019; 63-65.
- 5: Fausto Fama, Miles G. Berry, Cecile Linard, et al. Multicentric Castleman Disease: An Unusual Breast Lump. *Journal of*

- Clinical Oncology. 2009; Volume 27: Issue 28 (DOI:10.1200/LCO.2009.22.4287)
- 6: Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. *Ann Surg.* 2012; 255(4):677–84 (DOI:10.1097/SLA.0b013e318249dcdc)
 - 7: Gldođan CE, Yksel C, etinkaya E, Ersz Ő, Gndođdu E, Berkem H. An Unusual Axillary Mass: Castleman's Disease. *Clin Surg.* 2017; 2: 1350.
 - 8: Fukuoka, M., Ueno, T., Yoshida, K., Kikuchi, M., Takeuchi, K., & Ohno, S. Breast castleman disease. *The Breast Journal.* May 2020. (DOI:10.1111/tbj.13902)
 - 9: Melikian AL, et al. Clinical and morphological features of different types of Castleman's disease. *Ter Arkh.* 2015; 87 (7):64–71. (DOI:10.17116/terarkh201587764-71)
 - 10: Rafael Parra-Medina, Jos Ismael Guio, Patricia Lpez-Correa, "Localized Castleman's Disease in the Breast in a Young Woman", *Case Reports in Pathology*, vol. 2016, Article ID 8413987 (DOI:10.1155/2016/8413987)
-